» Articles » PMID: 12917399

Alternative Splicing of the Human Cyclin D-binding Myb-like Protein (hDMP1) Yields a Truncated Protein Isoform That Alters Macrophage Differentiation Patterns

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Aug 15
PMID 12917399
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

We have cloned two novel, alternatively spliced messages of human cyclin D-binding Myb-like protein (hDMP1). The known, full-length protein has been named hDMP1alpha and the new isoforms, hDMP1beta and hDMP1gamma. The hDMP1alpha, -beta, and -gamma splice variants have unique expression patterns in normal hematopoietic cells; hDMP1beta mRNA transcripts are strongly expressed in quiescent CD34+ cells and freshly isolated peripheral blood leukocytes, as compared with hDMP1alpha. In contrast, activated T-cells and developing myeloid cells, macrophages, and granulocytes express low levels of hDMP1beta transcripts, and hDMP1gamma is ubiquitously and weakly expressed. Mouse Dmp1 has been shown to activate CD13/aminopeptidase N (APN) and p19ARF gene expression via binding to canonical DNA recognition sites in the respective promoters. Assessment of CD13/APN promoter responsiveness demonstrated that hDMP1alpha but not hDMP1beta and -gamma, is a transcriptional activator. Furthermore, hDMP1beta was found to inhibit the CD13/APN promoter transactivation ability of hDMP1alpha. Stable, ectopic expression of hDMP1beta and, to a lesser extent hDMP1gamma, reduced endogenous cell surface levels of CD13/APN in U937 cells. Moreover, stable, ectopic expression of hDMP1beta altered phorbol 12-myristate 13-acetate-induced terminal differentiation of U937 cells to macrophages and resulted in maintenance of proliferation. These results demonstrate that hDMP1beta antagonizes hDMP1alpha activity and suggest that cellular functions of hDMP1 may be regulated by cellular hDMP1 isoform levels.

Citing Articles

Engineered Zinc Finger Protein Targeting 2LTR Inhibits HIV Integration in Hematopoietic Stem and Progenitor Cell-Derived Macrophages: In Vitro Study.

Chupradit K, Khamaikawin W, Sakkhachornphop S, Puaninta C, Torbett B, Borwornpinyo S Int J Mol Sci. 2022; 23(4).

PMID: 35216446 PMC: 8875109. DOI: 10.3390/ijms23042331.


Restriction of extracellular lipids renders pancreatic cancer dependent on autophagy.

Saliakoura M, Rossi Sebastiano M, Nikdima I, Pozzato C, Konstantinidou G J Exp Clin Cancer Res. 2022; 41(1):16.

PMID: 34998392 PMC: 8742413. DOI: 10.1186/s13046-021-02231-y.


EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs).

April-Monn S, Andreasi V, Schiavo Lena M, Sadowski M, Kim-Fuchs C, Buri M Cancers (Basel). 2021; 13(19).

PMID: 34638497 PMC: 8508156. DOI: 10.3390/cancers13195014.


SRSF5 regulates alternative splicing of pre-mRNA through modulating SF1 binding.

Li J, Li G, Qi Y, Lu Y, Wang H, Shi K RNA Biol. 2021; 18(sup1):318-336.

PMID: 34291726 PMC: 8677014. DOI: 10.1080/15476286.2021.1947644.


PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.

Ercolano G, Gomez-Cadena A, Dumauthioz N, Vanoni G, Kreutzfeldt M, Wyss T Nat Commun. 2021; 12(1):2538.

PMID: 33953160 PMC: 8100153. DOI: 10.1038/s41467-021-22764-2.